Cotadutide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Trial Timeline
Jul 14, 2022 → Apr 19, 2024
NCT ID
NCT05364931About Cotadutide + Placebo
Cotadutide + Placebo is a phase 2 stage product being developed by AstraZeneca for Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05364931. Target conditions include Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05364931 | Phase 2 | Completed |
Competing Products
1 competing product in Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4831 | AstraZeneca | Phase 2 | 52 |